Eliem Therapeutics, Inc. (ELYM)
NASDAQ: ELYM · IEX Real-Time Price · USD
4.180
-0.250 (-5.64%)
At close: Apr 18, 2024, 4:00 PM
4.200
+0.020 (0.48%)
After-hours: Apr 18, 2024, 7:57 PM EDT
Company Description
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems.
Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.
The company was incorporated in 2018 and is headquartered in Redmond, Washington.
Eliem Therapeutics, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Aug 10, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Dr. Andrew Levin M.D., Ph.D. |
Contact Details
Address: 2801 Centerville Road 1st Floor, Pmb #117 Wilmington, Delaware 19808 United States | |
| Phone | 877-354-3689 |
| Website | eliemtx.com |
Stock Details
| Ticker Symbol | ELYM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $12.50 |
| CIK Code | 0001768446 |
| CUSIP Number | 28658R106 |
| ISIN Number | US28658R1068 |
| Employer ID | 83-2273741 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew Levin M.D., Ph.D. | Principal Financial Officer and Executive Chairman |
| Dr. Valerie Morisset Ph.D. | Chief Scientific Officer and Executive Vice President of Research and Development |
| Emily Pimblett | Principal Accounting Officer |
| Jo Palmer-Phillips Ph.D. | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Apr 11, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 11, 2024 | 8-K | Current Report |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 19, 2024 | 8-K | Current Report |
| Mar 18, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 17, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 14, 2023 | 10-Q | Quarterly Report |